hVIVO plc (LON:HVO - Get Free Report) dropped 6.8% during trading on Thursday . The company traded as low as GBX 19 ($0.24) and last traded at GBX 19.10 ($0.24). Approximately 2,518,262 shares changed hands during mid-day trading, a decline of 26% from the average daily volume of 3,389,765 shares. The stock had previously closed at GBX 20.50 ($0.25).
hVIVO Price Performance
The stock has a market cap of £129.95 million, a price-to-earnings ratio of 636.67 and a beta of 0.97. The company has a debt-to-equity ratio of 33.86, a current ratio of 1.61 and a quick ratio of 1.16. The stock's 50 day simple moving average is GBX 23.58 and its two-hundred day simple moving average is GBX 26.77.
hVIVO Company Profile
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
See Also
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
